What is the next catalyst for Editas Medicine (EDIT)?

The next dated event is Phase 1/2 start (Strive) for EDIT-401, expected By year-end 2026, as stated by the company. Also ahead: Phase 1/2 interim results (Strive) for EDIT-401, expected Q1 2027.

How long will Editas Medicine's cash last?

Editas Medicine has said its cash will fund operations into H2 2028 (guidance as of August 5, 2026).

EDITEditas Medicine, Inc.

Market reactionShares fell 10% on Nov 5.

IntactLast material event Aug 5, 2026 · Updated Oct 25, 2026

Editas received approval to start its first EDIT-401 trial in Australia and expects to dose patients this year, with initial safety data in the first quarter of 2027; cash of $211.6 million is expected to last into the second half of 2028

Editas Medicine is a clinical-stage company developing EDIT-401, a one-time in vivo gene-editing treatment designed to lower LDL cholesterol; it is not approved.

Editas' case rests on EDIT-401, a one-time in vivo CRISPR edit of the LDLR gene that cut LDL cholesterol by about 90% or more in monkeys. The Phase 1/2 Strive trial has ethics approval in Australia, with dosing expected to begin in 2026 and initial safety data in the first quarter of 2027. Efficacy data are now expected later in 2027, not by the end of 2026, and cash of $211.6 million should fund operations into the second half of 2028.

Thesis checklist

0 risks need attention

Select a row for evidence

What must be trueStateNext proof

Initial Strive data show EDIT-401 is safeAwaiting evidenceInitial safety and tolerability data (first quarter of 2027).Next: Initial safety and tolerability data (first quarter of 2027).

Why it is in this state

The evidence, what would weaken it and the source filing

Strive doses its first patients in 2026Awaiting evidenceFirst patient dosed (by year-end 2026).Next: First patient dosed (by year-end 2026).

Why it is in this state

The evidence, what would weaken it and the source filing

Part 1 shows deep LDL cholesterol loweringAwaiting evidencePart 1 topline data (later in 2027).Next: Part 1 topline data (later in 2027).

Why it is in this state

The evidence, what would weaken it and the source filing

Cash lasts into the second half of 2028SupportedQ3 cash balance.Next: Q3 cash balance.

Why it is in this state

The evidence, what would weaken it and the source filing

Next decision point

Initial Strive safety and tolerability data

Tests: Initial Strive data show EDIT-401 is safe

First quarter of 2027

Is EDIT-401 safe and well tolerated in the first patients, so dose escalation can continue?

Strong, inconclusive and weak outcomes

What to look for in the result and how each would move the checklist

Questions to investigate

History

Price and material events

Select an event marker to read the update below. Marker colors show Thesis status.

IntactCurrentClinical

+5.5%Aug 5, 2026

Editas received approval to start its first EDIT-401 trial in Australia and expects to dose patients this year, with initial safety data in the first quarter of 2027; cash of $211.6 million is expected to last into the second half of 2028

ChallengedFinancial

+15.9%May 26, 2026

EDIT-401's first-in-human LDL-C data in HeFH will determine whether preclinical gene editing efficacy translates to humans before cash runs out

IntactRegulatory

-3.9%Sep 2, 2025

EDIT-401's first-in-human HeFH trial tests whether NHP-level LDL-C reduction translates to humans before cash runs out in Q3 2027

About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.

Pipeline

Heterozygous familial hypercholesterolemia

EDIT-401 · 4 upcoming · 1 completed

Phase 1/2 Study InitiationStriveAustralia

By year-end 2026

Phase 1/2 Data: InterimStrive

Q1 2027

Phase 1/2 Data: ToplineStrive

Later in 2027

Phase 1/2 (Part 2) Study InitiationStrive

TBD

Blood disorder· Liver disease

In vivo gene editing · 1 completed

Declare Two Development Candidates

Reported Aug 12, 2025

Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.

Quick answers

Is the Editas Medicine (EDIT) investment thesis intact?: Yes. Readouts currently rates the Editas Medicine Thesis Intact. Editas received approval to start its first EDIT-401 trial in Australia and expects to dose patients this year, with initial safety data in the first quarter of 2027; cash of $211.6 million is expected to last into the second half of 2028.
What is the next catalyst for Editas Medicine (EDIT)?: The next dated event is Phase 1/2 start (Strive) for EDIT-401, expected By year-end 2026, as stated by the company. Also ahead: Phase 1/2 interim results (Strive) for EDIT-401, expected Q1 2027.
How long will Editas Medicine's cash last?: Editas Medicine has said its cash will fund operations into H2 2028 (guidance as of August 5, 2026).

Other companies we cover in these diseases

Heterozygous familial hypercholesterolemia: NewAmsterdam Pharma Company (NAMS)Silence Therapeutics (SLN)

Disease areas: Obesity, diabetes and heart disease
Catalyst calendar · Upcoming FDA decisions · Thesis changes

Competitive landscape

4 peers tracked

Financial snapshot

Dates and calculation details

Cash: Market-data provider estimate; measurement period unavailable.

Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.

Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.

Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.

Runway: No underlying guidance available.